Trial site
Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship 27-400, PolandEU-13 widening countryNot linked to an institution yet
- 14running trials
- 22closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Phase
- Phase 321 trials
- Phase 213 trials
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed22 trials
- Active, not recruiting9 trials
- Not yet recruiting3 trials
- Recruiting2 trials
- Lead sponsor
- Chiesi Farmaceutici S.p.A.7 trials
- Sanofi6 trials
- AstraZeneca4 trials
- GlaxoSmithKline2 trials
- Takeda2 trials
- and 14 more
Running trials
Not yet recruiting
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source
Recruiting
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· Phase 2/3· Pfizer· Source
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· Phase 2· CSL Behring· Source
Active, not recruiting
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479· Phase 2· Upstream Bio Inc.· Source
Active, not recruiting
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· Phase 2· Sanofi· Source
Enrolling by invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239· Phase 2· Sanofi· Source
Active, not recruiting
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· Phase 3· Takeda· Source
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443· Phase 2· Incyte Corporation· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD)
2024-516714-37-00· Phase 3· Medical University Of Bialystok· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Not yet recruiting
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
NCT06731959· Phase 2· Aer Therapeutics· Source
Completed
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045· Phase 2· Amgen Inc.· Source
Completed
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
NCT06261957· Phase 3· GlaxoSmithKline· Source
Completed
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879· Phase 2· Upstream Bio Inc.· Source
Completed
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391· Phase 2· Sanofi· Source
Completed
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· Phase 3· Sanofi· Source
Completed
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy
2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· Phase 3· Takeda· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2)
2023-507665-25-00· Phase 3· Areteia Therapeutics Inc.· Source
Completed
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600· Phase 3· Areteia Therapeutics· Source
Completed
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
NCT05398263· Phase 3· AstraZeneca AB· Source
Completed
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
NCT05243680· Phase 3· GlaxoSmithKline· Source
Completed
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
NCT05158387· Phase 3· AstraZeneca· Source
Completed
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)
2023-507093-40-00· Phase 2· Genentech Inc.· Source
Completed
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy
NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04751487· Phase 3· Sanofi· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04701983· Phase 3· Sanofi· Source
Completed
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
NCT04053634· Phase 3· AstraZeneca· Source
Report an error